These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 36255682)

  • 61. Reduction of cerebral edema with GM1 ganglioside.
    Karpiak SE; Mahadik SP
    J Neurosci Res; 1984; 12(2-3):485-92. PubMed ID: 6094838
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Gangliosides and parkinsonism.
    Herrero MT; Kastner A; Perez-Otaño I; Hirsch EC; Luquin MR; Javoy-Agid F; Del Río J; Obeso JA; Agid Y
    Neurology; 1993 Oct; 43(10):2132-4. PubMed ID: 8413979
    [TBL] [Abstract][Full Text] [Related]  

  • 63. GM1 ganglioside in Parkinson's disease: Results of a five year open study.
    Schneider JS; Sendek S; Daskalakis C; Cambi F
    J Neurol Sci; 2010 May; 292(1-2):45-51. PubMed ID: 20206941
    [TBL] [Abstract][Full Text] [Related]  

  • 64. GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice.
    Fazzini E; Durso R; Davoudi H; Szabo GK; Albert ML
    J Neurol Sci; 1990 Oct; 99(1):59-68. PubMed ID: 2250172
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of the 13C-N.M.R. spectra of gangliosides GM1 with those of GM1-oligosaccharide and asialo-GM1.
    Sillerud LO; Yu RK
    Carbohydr Res; 1983 Mar; 113(2):173-88. PubMed ID: 6839313
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients.
    Schneider JS; Gollomp SM; Sendek S; Colcher A; Cambi F; Du W
    J Neurol Sci; 2013 Jan; 324(1-2):140-8. PubMed ID: 23199590
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosides.
    Di Pasquale E; Fantini J; Chahinian H; Maresca M; Taïeb N; Yahi N
    J Mol Biol; 2010 Mar; 397(1):202-18. PubMed ID: 20114052
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Gangliosides in children with autism.
    Lekman A; Skjeldal O; Sponheim E; Svennerholm L
    Acta Paediatr; 1995 Jul; 84(7):787-90. PubMed ID: 7549298
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Occurrence of glycosylation and deglycosylation of exogenously administered ganglioside GM1 in mouse liver.
    Ghidoni R; Sonnino S; Chigorno V; Venerando B; Tettamanti G
    Biochem J; 1983 Aug; 213(2):321-9. PubMed ID: 6615438
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ganglioside composition in human meningiomas.
    Davidsson P; Fredman P; Collins VP; von Holst H; Mänsson JE; Svennerholm L
    J Neurochem; 1989 Sep; 53(3):705-9. PubMed ID: 2760617
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Genotype-related changes of ganglioside composition in brain regions of transgenic mouse models of Alzheimer's disease.
    Barrier L; Ingrand S; Damjanac M; Rioux Bilan A; Hugon J; Page G
    Neurobiol Aging; 2007 Dec; 28(12):1863-72. PubMed ID: 17007963
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High-performance capillary electrophoresis of gangliosides.
    Liu YB; Chan KF
    Electrophoresis; 1991 Jun; 12(6):402-8. PubMed ID: 1889389
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Regenerative capacity of the goldfish visual system is affected by antibodies specific to gangliosides injected intraocularly.
    Spirman N; Sela BA; Gitler C; Calef E; Schwartz M
    J Neuroimmunol; 1984 Jun; 6(3):197-207. PubMed ID: 6725551
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Anti-GM1 ganglioside antibodies with differing fine specificities in patients with multifocal motor neuropathy.
    Baba H; Daune GC; Ilyas AA; Pestronk A; Cornblath DR; Chaudhry V; Griffin JW; Quarles RH
    J Neuroimmunol; 1989 Dec; 25(2-3):143-50. PubMed ID: 2584393
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Neurotrophic effects of G
    Schwarz S; Lehmbecker A; Tongtako W; Hahn K; Wang Y; Felmy F; Zdora I; Brogden G; Branitzki-Heinemann K; von Köckritz-Blickwede M; Baumgärtner W; Gerhauser I
    Sci Rep; 2020 Mar; 10(1):5380. PubMed ID: 32214122
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Novel insights on GM1 and Parkinson's disease: A critical review.
    Fazzari M; Di Biase E; Lunghi G; Mauri L; Chiricozzi E; Sonnino S
    Glycoconj J; 2022 Feb; 39(1):27-38. PubMed ID: 35064857
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Localization of GM1 and GD1b antigens in the human peripheral nervous system.
    Kusunoki S; Chiba A; Tai T; Kanazawa I
    Muscle Nerve; 1993 Jul; 16(7):752-6. PubMed ID: 7685064
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Regional distribution of brain gangliosides in Alzheimer's disease.
    Kalanj S; Kracun I; Rosner H; Cosović C
    Neurol Croat; 1991; 40(4):269-81. PubMed ID: 1751644
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Measurement of antiganglioside autoantibodies by immunodot-blot assay: clinical importance in peripheral neuropathies].
    Caudie C; Vial C; Petiot P; Bancel J; Later R; Gonnaud PM
    Ann Biol Clin (Paris); 1999; 57(5):579-88. PubMed ID: 10518060
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Phase behavior of ganglioside-lecithin mixtures. Relation to dispersion of gangliosides in membranes.
    Bunow MR; Bunow B
    Biophys J; 1979 Sep; 27(3):325-37. PubMed ID: 263689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.